HomeCompareADGI vs MO

ADGI vs MO: Dividend Comparison 2026

ADGI yields 43.10% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADGI wins by $196.5K in total portfolio value
10 years
ADGI
ADGI
● Live price
43.10%
Share price
$4.64
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$274.2K
Annual income
$49,280.46
Full ADGI calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — ADGI vs MO

📍 ADGI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADGIMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADGI + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADGI pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADGI
Annual income on $10K today (after 15% tax)
$3,663.79/yr
After 10yr DRIP, annual income (after tax)
$41,888.39/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, ADGI beats the other by $17,265.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADGI + MO for your $10,000?

ADGI: 50%MO: 50%
100% MO50/50100% ADGI
Portfolio after 10yr
$175.9K
Annual income
$39,124.50/yr
Blended yield
22.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ADGI
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.2
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADGI buys
0
MO buys
11
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MO▲ Buy$1,000 - $15,0002025-08-04
Sheri Biggs🏢 House$MO▼ Sell$1,001 - $15,0002025-03-19
Pete Sessions🏢 House$MO▼ Sell$1,001 - $15,0002024-09-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-03-20
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-02-13
Virginia Foxx🏢 House$MO▼ Sell$1,001 - $15,0002024-01-16
Virginia Foxx🏢 House$MO▲ Buy$1,001 - $15,0002024-01-11
Ro Khanna🏢 House$MO▼ Sell$1,001 - $15,0002024-01-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-01-10
Virginia Foxx🏢 House$MO▼ Sell$15,001 - $50,0002024-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADGIMO
Forward yield43.10%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$274.2K$77.7K
Annual income after 10y$49,280.46$28,968.54
Total dividends collected$210.7K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ADGI vs MO ($10,000, DRIP)

YearADGI PortfolioADGI Income/yrMO PortfolioMO Income/yrGap
1← crossover$15,010$4,310.34$10,558$768.31+$4.5KADGI
2$22,108$6,046.71$11,352$1,015.87+$10.8KADGI
3$31,979$8,323.18$12,482$1,367.86+$19.5KADGI
4$45,469$11,251.72$14,103$1,883.39+$31.4KADGI
5$63,603$14,951.67$16,472$2,664.91+$47.1KADGI
6$87,602$19,546.64$20,024$3,897.79+$67.6KADGI
7$118,895$25,160.75$25,537$5,933.74+$93.4KADGI
8$159,132$31,914.57$34,478$9,476.77+$124.7KADGI
9$210,192$39,920.85$49,776$16,022.63+$160.4KADGI
10$274,186$49,280.46$77,699$28,968.54+$196.5KADGI

ADGI vs MO: Complete Analysis 2026

ADGIStock

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Full ADGI Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ADGI vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADGI vs SCHDADGI vs JEPIADGI vs OADGI vs KOADGI vs MAINADGI vs PMADGI vs BTIADGI vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.